At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business ...
Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...
The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...
The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK ...
Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...
Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...
Glucotrack, Inc., a medical technology company specializing in diabetes solutions, announced it has achieved ISO 13485:2016 certification from the British Standards Institute, marking a ...
Inc trading halted, news pendingMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...